Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics develops biopharmaceutical therapies for life-threatening immune and thrombotic conditions. News about Cadrenal Therapeutics centers on CAD-1005, its investigational selective 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia, including clinical-study results, FDA communications, pivotal-trial design guidance, and research involving the broader 12-LOX inhibitor platform.
Company updates also cover pipeline assets such as tecarfarin, an oral vitamin K antagonist for chronic anticoagulation settings, and frunexian, a parenteral Factor XIa inhibitor for acute hospital use. Recurring financial news includes quarterly results, cash resources, equity financings, and strategic alternatives tied to the company’s clinical development plans.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has provided a corporate update alongside its Annual Report for FY 2022. The company focuses on developing tecarfarin, a novel therapy with orphan drug and Fast Track designations from the FDA, aimed at preventing systemic thromboembolism in patients with end-stage renal disease (ESRD) and atrial fibrillation (AFib). Key highlights include the FDA's Fast Track designation for tecarfarin, the formation of a Scientific Advisory Board, and the successful completion of an IPO raising $7 million. A Phase 3 clinical trial, ACTOR-AF, is planned with the potential to address a significant market opportunity worth up to $1 billion annually if approved.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical firm, is advancing tecarfarin, a new therapy aimed at preventing systemic thromboembolism in patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib). During March, recognized as National Kidney Month, the company highlights the urgent need for effective treatments for this underserved group, which includes over 150,000 ESRD patients also suffering from AFib. With total Medicare spending for ESRD patients hitting $51 billion in 2019, tecarfarin's potential to reduce risks of stroke and mortality is significant. Currently, a Phase 3 clinical trial is being planned as the FDA shows interest.